Most researchers seeking out CJC-1295 in Gizy rapidly learn that local retail options are nearly impossible to find. What this means for Gizy researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those quality checks are within reach of all serious researchers. Separating properly characterised CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram confirming ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Gizy researchers the methodology to verify sourcing options methodically and source verified-quality CJC-1295 with confidence.
CJC-1295 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Gizy comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Evaluating CJC-1295 vendors starts with the COA: request the batch-specific certificate prior to buying, not after. Mass spectrometry in the COA establishes that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone does not confirm what the compound actually is. For Gizy researchers evaluating vendors with limited track records: a small initial order to verify quality before scaling up your order is what experienced peptide researchers consistently do. The lyophilised (freeze-dried) form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Gizy
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution kept at 2-8°C refrigerated and finished within 30 days of reconstitution; reconstitute only with bac water. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results expressed as EU/mg or EU/mL and compare against acceptable research limits for your application. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is unapproved for human therapeutic application and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
